The estimated Net Worth of Vignesh Rajah is at least $478 Tausend dollars as of 5 March 2024. Dr Rajah owns over 1,711 units of Y-Mabs Therapeutics Inc stock worth over $449,707 and over the last 4 years he sold YMAB stock worth over $28,283.
Dr has made over 4 trades of the Y-Mabs Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,711 units of YMAB stock worth $28,283 on 5 March 2024.
The largest trade he's ever made was selling 1,711 units of Y-Mabs Therapeutics Inc stock on 5 March 2024 worth over $28,283. On average, Dr trades about 543 units every 109 days since 2020. As of 5 March 2024 he still owns at least 33,889 units of Y-Mabs Therapeutics Inc stock.
You can see the complete history of Dr Rajah stock trades at the bottom of the page.
Dr. Vignesh Rajah is the Sr. VP & Chief Medical Officer at Y-Mabs Therapeutics Inc.
Vignesh's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK, NY, 10169.
Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad und Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include: